During the past decade, Regional Cancer Care conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regional Cancer Care" #1 collaborator was "US Oncology Research" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Regional Cancer Care" are "Metastatic Breast Cancer" (1 trials) and "Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Regional Cancer Care" in a lesser frequency.

Most popular intervention types in "Regional Cancer Care" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Amrubicin" (1 trials), "Ixabepilone" (1 trials) and "Topotecan" (1 trials). Other intervention names were less common.

The vast majority of trials in "Regional Cancer Care" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Regional Cancer Care". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Regional Cancer Care, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Regional Cancer Care, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".